MNKD

MannKind (NASDAQ: MNKD) was upgraded by equities research analysts at JPMorgan Chase from an “underweight” rating to a “neutral” rating in a research note issued to investors on Friday.

MNKD has been the subject of a number of other recent research reports. Analysts at Zacks reiterated a “neutral” rating on shares of MannKind in a research note to investors on Wednesday, October 17th. They now have a $2.75 price target on the stock. Separately, analysts at JMP Securities upgraded shares of MannKind from a “market perform” rating to a “market outperform” rating in a research note to investors on Friday, August 10th.

MannKind opened at 1.9283 on Friday. MannKind has a 52-week low of $1.57 and a 52-week high of $3.48. The company’s market cap is $367.0 million.

MannKind last posted its quarterly earnings results on Thursday, November 1st. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.02. On average, analysts predict that MannKind will post $-0.90 earnings per share for the current fiscal year.

MannKind Corporation (MannKind) is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases, such as diabetes and cancer.